Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND, AUG. 12, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING OPHTHALMIC AND NEURO-OPHTHALMIC CONDITIONS WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT OCULIS' MANAGEMENT WILL BE PARTICIPATING IN THE H.C. WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE ON AUGUST 13, 2025.

OCULIS TO PARTICIPATE IN UPCOMING H.C. WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE

ZUG, SWITZERLAND, AUG. 12, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING OPHTHALMIC AND NEURO-OPHTHALMIC CONDITIONS WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT OCULIS' MANAGEMENT WILL BE PARTICIPATING IN THE H.C WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE ON AUGUST 13, 2025.

OCULIS TO PARTICIPATE IN UPCOMING H.C WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE

ZUG, SWITZERLAND, AUG. 01, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING OPHTHALMIC AND NEURO-OPHTHALMIC DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS AMENDED ITS LOAN FACILITY (THE AMENDED LOAN AGREEMENT) WITH FUNDS AND ACCOUNTS MANAGED BY BLACKROCK (THE LENDER).

OCULIS UPSIZED LOAN FACILITY TO ACCESS UP TO CHF 100 MILLION

ZUG, SWITZERLAND, JULY 09, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING AND SETTLEMENT OF RSUS PREVIOUSLY GRANTED TO DIRECTORS OF THE COMPANY.

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

ZUG, SWITZERLAND, JUNE 05, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (OCULIS OR THE COMPANY), TODAY ANNOUNCED THE RESULTS FROM ITS 2025 ANNUAL GENERAL MEETING HELD ON JUNE 4, 2025 AT OCHSEN-ZUG, KOLINPLATZ 11, CH-6300 ZUG, SWITZERLAND, AT 3:00 P.M. CEST / 9:00 A.M. EDT.

OCULIS PUBLISHES RESULTS OF 2025 ANNUAL GENERAL MEETING

ZUG, SWITZERLAND, JUNE 03, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATIONS RELATE TO THE VESTING AND SETTLEMENT OF RSUS PREVIOUSLY GRANTED TO DIRECTORS OF THE COMPANY.

ZUG, SWITZERLAND, JUNE 03, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / ICX: OCS.IC) (OCULIS), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING OPHTHALMIC AND NEURO-OPHTHALMIC DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT OCULIS WILL BE PARTICIPATING IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

OCULIS TO PARTICIPATE IN UPCOMING JUNE INVESTOR CONFERENCES

ZUG, SWITZERLAND, MAY 09, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / ICX: OCS.IC) (OCULIS), TODAY PUBLISHED THE INVITATION TO THE 2025 ANNUAL GENERAL MEETING, WHICH WILL BE HELD ON JUNE 4, 2025 AT OCHSEN-ZUG, KOLINPLATZ 11, CH-6300 ZUG, SWITZERLAND, AT 3:00 P.M. CEST / 9:00 A.M. EDT.

OCULIS PUBLISHES INVITATION TO THE ANNUAL GENERAL MEETING

ZUG, SWITZERLAND, MAY 08, 2025 (GLOBE NEWSWIRE) -- THE RECENT R&D DAY ( REPLAY ) SHOWCASED MATERIAL PROGRESS ACROSS ALL THREE CORE ASSETS AND HIGHLIGHTED POTENTIAL FIRST-IN-CLASS NEUROPROTECTION TREATMENT IN NEURO-OPHTHALMOLOGY, AN AREA OF HIGH UNMET MEDICAL NEED, THANKS TO PRIVOSEGTOR'S (OCS-05) POSITIVE RESULTS FROM THE ACUITY TRIAL IN ACUTE OPTIC NEURITIS OCS-01: DIAMOND PH3 TRIALS ENROLLMENT COMPLETED WITH OVER 800 PATIENTS RANDOMIZED; TOPLINE RESULTS EXPECTED Q2 2026 FOR THE FIRST POTENTIAL EYE DROP TREATMENT FOR DIABETIC MACULAR EDEMA (DME) LICAMINLIMAB (OCS-02) GENOTYPE-BASED DEVELOPMENT PLAN TO DRIVE A PERSONALIZED MEDICINE APPROACH IN DRY EYE DISEASE (DED) ALIGNED WITH FDA; FIRST REGISTRATIONAL TRIAL INITIATION ANTICIPATED IN 2H 2025 CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $206.3 MILLION AS OF MARCH 31, 2025, REFLECTS PROCEEDS FROM THE $100.0 MILLION FINANCING IN FEBRUARY 2025, PROVIDING CASH RUNWAY INTO EARLY 2028 OCULIS HOLDING AG (NASDAQ: OCS / ICX: OCS.IC) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING OPHTHALMIC AND NEURO-OPHTHALMIC DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED AN OVERVIEW OF THE COMPANY'S PROGRESS. RIAD SHERIF M.D.

OCULIS REPORTS Q1 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

THE RECENT R&D DAY ( REPLAY ) SHOWCASED MATERIAL PROGRESS ACROSS ALL THREE CORE ASSETS AND HIGHLIGHTED POTENTIAL FIRST-IN-CLASS NEUROPROTECTION TREATMENT IN NEURO-OPHTHALMOLOGY, AN AREA OF HIGH UNMET MEDICAL NEED, THANKS TO PRIVOSEGTOR'S (OCS-05) POSITIVE RESULTS FROM THE ACUITY TRIAL IN ACUTE OPTIC NEURITIS OCS-01: DIAMOND PH3 TRIALS ENROLLMENT COMPLETED WITH OVER 800 PATIENTS RANDOMIZED; TOPLINE RESULTS EXPECTED Q2 2026 FOR THE FIRST POTENTIAL EYE DROP TREATMENT FOR DIABETIC MACULAR EDEMA (DME) LICAMINLIMAB (OCS-02) GENOTYPE-BASED DEVELOPMENT PLAN TO DRIVE A PERSONALIZED MEDICINE APPROACH IN DRY EYE DISEASE (DED) ALIGNED WITH FDA; FIRST REGISTRATIONAL TRIAL INITIATION ANTICIPATED IN 2H 2025 CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $206.3 MILLION AS OF MARCH 31, 2025, REFLECTS PROCEEDS FROM THE $100.0 MILLION FINANCING IN FEBRUARY 2025, PROVIDING CASH RUNWAY INTO EARLY 2028 ZUG, SWITZERLAND, MAY 08, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / ICX: OCS.IC) (OCULIS OR THE COMPANY), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIONS ADDRESSING OPHTHALMIC AND NEURO-OPHTHALMIC DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED AN OVERVIEW OF THE COMPANY'S PROGRESS. RIAD SHERIF M.D.

Oculis Holding AG

OCS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Oculis Holding AG

OCS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OCS